These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 29095257)

  • 1. Efficacy and safety of bevacizumab treatment for refractory brain edema: Case report.
    Meng X; Zhao R; Shen G; Dong D; Ding L; Wu S
    Medicine (Baltimore); 2017 Nov; 96(44):e8280. PubMed ID: 29095257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of bevacizumab in the treatment of refractory brain edema of metastatic tumors from different sources.
    Bai X; Zhang Y; Ding W; Wang S
    Neurol Res; 2021 Dec; 43(12):955-960. PubMed ID: 34766548
    [No Abstract]   [Full Text] [Related]  

  • 3. Single-shot bevacizumab for cerebral radiation injury.
    Voss M; Wenger KJ; Fokas E; Forster MT; Steinbach JP; Ronellenfitsch MW
    BMC Neurol; 2021 Feb; 21(1):77. PubMed ID: 33596839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Safety and Efficacy of Bevacizumab for Radiosurgery - Induced Steroid - Resistant Brain Edema; Not the Last Part in the Ship of Theseus.
    Tripathi M; Ahuja CK; Mukherjee KK; Kumar N; Dhandapani S; Dutta P; Kaur R; Rekhapalli R; Batish A; Gurnani J; Kamboj P; Agrahari A; Kataria K
    Neurol India; 2019; 67(5):1292-1302. PubMed ID: 31744962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bevacizumab in the Treatment of Refractory Brain Edema in High-grade Glioma.
    Alsahlawi AK; Michaud-Couture C; Lachance A; Bergeron-Gravel S; Létourneau M; Bourget C; Gould PV; Giannakouros P; Nakada EM; Faury D; Crevier L; Bouffet É; Jabado N; Larouche V; Renzi S
    J Pediatr Hematol Oncol; 2024 Jan; 46(1):e87-e90. PubMed ID: 38032194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Variables for Prediction of the Therapeutic Effects of Bevacizumab Monotherapy in Nasopharyngeal Carcinoma Patients With Radiation-Induced Brain Necrosis.
    Li Y; Huang X; Jiang J; Hu W; Hu J; Cai J; Rong X; Cheng J; Xu Y; Wu R; Luo J; Tang Y
    Int J Radiat Oncol Biol Phys; 2018 Mar; 100(3):621-629. PubMed ID: 29413276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bevacizumab used for the treatment of severe, refractory perilesional edema due to an arteriovenous malformation treated with stereotactic radiosurgery.
    Williams BJ; Park DM; Sheehan JP
    J Neurosurg; 2012 May; 116(5):972-7. PubMed ID: 22324417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vascular endothelial growth factor blockade alters magnetic resonance imaging biomarkers of vascular function and decreases barrier permeability in a rat model of lung cancer brain metastasis.
    Pishko GL; Muldoon LL; Pagel MA; Schwartz DL; Neuwelt EA
    Fluids Barriers CNS; 2015 Feb; 12():5. PubMed ID: 25879723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single low-dose targeted bevacizumab infusion in adult patients with steroid-refractory radiation necrosis of the brain: a phase II open-label prospective clinical trial.
    Dashti SR; Kadner RJ; Folley BS; Sheehan JP; Han DY; Kryscio RJ; Carter MB; Shields LBE; Plato BM; La Rocca RV; Spalding AC; Yao TL; Fraser JF
    J Neurosurg; 2022 Dec; 137(6):1676-1686. PubMed ID: 35426830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intratumoral and peritumoral post-irradiation changes, but not viable tumor tissue, may respond to bevacizumab in previously irradiated meningiomas.
    Furuse M; Nonoguchi N; Kawabata S; Miyata T; Toho T; Kuroiwa T; Miyatake S
    Radiat Oncol; 2015 Jul; 10():156. PubMed ID: 26223253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bevacizumab for critical brain metastases in a patient with pulmonary pleomorphic carcinoma.
    Hata A; Fujita S; Takayama K; Katakami N
    Intern Med; 2014; 53(16):1813-8. PubMed ID: 25130117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Restriction spectrum imaging predicts response to bevacizumab in patients with high-grade glioma.
    McDonald CR; Delfanti RL; Krishnan AP; Leyden KM; Hattangadi-Gluth JA; Seibert TM; Karunamuni R; Elbe P; Kuperman JM; Bartsch H; Piccioni DE; White NS; Dale AM; Farid N
    Neuro Oncol; 2016 Nov; 18(11):1579-1590. PubMed ID: 27106406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pilot study to determine the timing and effect of bevacizumab on vascular normalization of metastatic brain tumors in breast cancer.
    Chen BB; Lu YS; Lin CH; Chen WW; Wu PF; Hsu CY; Yu CW; Wei SY; Cheng AL; Shih TT
    BMC Cancer; 2016 Jul; 16():466. PubMed ID: 27412562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-agent bevacizumab in the treatment of recurrent or refractory pediatric low-grade glioma: A single institutional experience.
    Gorsi HS; Khanna PC; Tumblin M; Yeh-Nayre L; Milburn M; Elster JD; Crawford JR
    Pediatr Blood Cancer; 2018 Sep; 65(9):e27234. PubMed ID: 29750399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differentiation between vasogenic-edema versus tumor-infiltrative area in patients with glioblastoma during bevacizumab therapy: a longitudinal MRI study.
    Artzi M; Bokstein F; Blumenthal DT; Aizenstein O; Liberman G; Corn BW; Ben Bashat D
    Eur J Radiol; 2014 Jul; 83(7):1250-1256. PubMed ID: 24809637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinetics of tumor size and peritumoral brain edema before, during, and after systemic therapy in recurrent WHO grade II or III meningioma.
    Furtner J; Schöpf V; Seystahl K; Le Rhun E; Rudà R; Roelcke U; Koeppen S; Berghoff AS; Marosi C; Clement P; Faedi M; Watts C; Wick W; Soffietti R; Weller M; Preusser M
    Neuro Oncol; 2016 Mar; 18(3):401-7. PubMed ID: 26354929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted intraarterial anti-VEGF therapy for medically refractory radiation necrosis in the brain.
    Dashti SR; Spalding A; Kadner RJ; Yao T; Kumar A; Sun DA; LaRocca R
    J Neurosurg Pediatr; 2015 Jan; 15(1):20-5. PubMed ID: 25360851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decrease in the apparent diffusion coefficient in peritumoral edema for the assessment of recurrent glioblastoma treated by bevacizumab.
    Takano S; Kimu H; Tsuda K; Osuka S; Nakai K; Yamamoto T; Ishikawa E; Akutsu H; Matsuda M; Matsumura A
    Acta Neurochir Suppl; 2013; 118():185-9. PubMed ID: 23564129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A study on the evaluation method and recent clinical efficacy of bevacizumab on the treatment of radiation cerebral necrosis.
    Zhuang H; Yuan X; Zheng Y; Li X; Chang JY; Wang J; Wang X; Yuan Z; Wang P
    Sci Rep; 2016 Apr; 6():24364. PubMed ID: 27067388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The benefit of bevacizumab therapy in patients with refractory vasogenic edema caused by brain metastasis from lung and colon cancers.
    Bai X; Zhou M
    Front Oncol; 2022; 12():838670. PubMed ID: 36249059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.